Core Insights - The main business of the company includes research, production, and sales of pharmaceuticals and health foods, as well as medical diagnostic services, genetic preservation, and pregnancy environment testing [2] - The core products are primarily categorized into urological drugs and nephrology drugs, with urological drugs accounting for the highest revenue share at 23.41%, followed by nephrology drugs at 2.94% [2] Financial Performance - In 2011, the company achieved a net profit attributable to shareholders of 0.35 billion yuan, which increased to 0.42 billion yuan by the end of the latest complete fiscal year in 2024, reflecting a cumulative growth of 19.37% over the years [2] - The company experienced losses in 3 out of the 14 years since its listing, with net profit growth occurring in 6 years, representing 42.86% of the time [2] - Revenue remained stable, with 8.48 billion yuan in 2020 and 8.47 billion yuan in 2024, indicating consistent revenue performance [3] - The company transitioned from a loss of 2.62 billion yuan in 2020 to a net profit of 0.42 billion yuan in 2024, demonstrating a successful turnaround [3] Market Valuation - Since its listing, the company's market value has increased by 0.32 times, peaking at 105.13 billion yuan on June 15, 2015, with a corresponding stock price of 65.48 yuan [5] - As of August 18, the stock price was 11.97 yuan, and the market value was 29.72 billion yuan, indicating a decrease of 75.41 billion yuan from its peak, resulting in a market value evaporation of 71.73% [5]